rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
12
|
pubmed:dateCreated |
2009-11-11
|
pubmed:abstractText |
The multikinase inhibitor dasatinib exerts growth-inhibitory effects in patients with imatinib-resistant chronic myeloid leukaemia (CML). In first clinical trials, side effects of dasatinib, 140 mg daily, were reported to be mild and tolerable.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1365-2362
|
pubmed:author |
pubmed-author:BöhmAA,
pubmed-author:BaumgartnerCC,
pubmed-author:BennettKK,
pubmed-author:HerndlhoferSS,
pubmed-author:HerrmannHH,
pubmed-author:JägerUU,
pubmed-author:RixUU,
pubmed-author:SillaberCC,
pubmed-author:Superti-FurgaGG,
pubmed-author:TschachlerEE,
pubmed-author:ValentPP
|
pubmed:issnType |
Electronic
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1098-109
|
pubmed:meshHeading |
pubmed-meshheading:19744184-Adult,
pubmed-meshheading:19744184-Aged,
pubmed-meshheading:19744184-Antigens, Neoplasm,
pubmed-meshheading:19744184-Antineoplastic Agents,
pubmed-meshheading:19744184-Basophils,
pubmed-meshheading:19744184-Female,
pubmed-meshheading:19744184-Flow Cytometry,
pubmed-meshheading:19744184-Humans,
pubmed-meshheading:19744184-Immunoglobulins,
pubmed-meshheading:19744184-Immunosuppressive Agents,
pubmed-meshheading:19744184-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:19744184-Lymphocytes,
pubmed-meshheading:19744184-Male,
pubmed-meshheading:19744184-Middle Aged,
pubmed-meshheading:19744184-Proteome,
pubmed-meshheading:19744184-Pyrimidines,
pubmed-meshheading:19744184-Thiazoles
|
pubmed:year |
2009
|
pubmed:articleTitle |
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
|
pubmed:affiliation |
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|